Improving diagnosis and treatment of mediastinal diseases using ultrasound techniques

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the effectiveness of intrapacial ultrasound-guided mediastinal opening techniques for diagnosing and treating mediastinal diseases. It will compare outcomes between patients undergoing this innovative technique and those receiving standard care. The study focuses on determining whether this approach provides greater clinical benefits, particularly in the diagnosis of benign versus malignant conditions and in the ablation of mediastinal masses. Participants will undergo procedures that may include biopsies and various ablation methods such as freezing or laser treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Radiographic abnormalities of mediastinum
* Can tolerate general anesthesia
* Can tolerate bronchoscopy and has the condition to have mediastinal biopsy and treatment

Exclusion Criteria:

* Imaging or other tests can make a definitive diagnosis
* Cannot tolerate general anesthesia or tracheoscopic surgery
* Patients cannot sign informed consent forms

Where it's running

• Tianjin Medical University General Hospital
  Tianjin, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Memory-Enhanced CAR-T Therapy for Relapsed/Refractory Large B-Cell Lymphoma

  This trial tests memory-enhanced 7×19-THEMIS CAR-T cells in adults with relapsed or refractory large B-cell lymphoma to see how safe they are and whether tumors shrink or disappear.

  Recruiting Phase 1/2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07788118

• TC011 (CD19 CAR-T) for relapsed or refractory large B‑cell lymphoma

  This will test a CD19-targeted CAR-T therapy called TC011 in adults whose large B‑cell lymphoma has relapsed or not responded after prior treatments.

  Recruiting Phase 1/2 TICAROS Co., Ltd. · Seoul, Seoul · NCT07473167

• Treatment for relapsed or refractory B-cell lymphoma using SynKIR-310

  This study is testing a new treatment called SynKIR-310 to see if it can help adults with relapsed or refractory B-cell lymphoma feel better.

  Recruiting at 5 sites Phase 1 Verismo Therapeutics · Denver, Colorado and 4 other locations · NCT06544265

• Gene therapy for certain blood cancers

  This study is testing a new gene therapy called VNX-101 to see if it can help people with certain types of blood cancers that haven't responded to other treatments.

  Recruiting at 11 sites Phase 1/2 Vironexis Biotherapeutics Inc. · Duarte, California and 10 other locations · NCT06533579

• Treatment of relapsed large B-cell lymphoma with WZTL-002 CAR T-cells

  This study is testing a new CAR T-cell therapy called WZTL-002 to see if it can help adults with relapsed large B-cell lymphoma that hasn't worked with standard chemotherapy.

  Recruiting at 3 sites Phase 2 Malaghan Institute of Medical Research · Auckland, Auckland and 2 other locations · NCT06486051

• Observational study on CAR-T therapy for lymphoma in Italy

  This study looks at how well CAR-T therapy works and its side effects for people with lymphoma in Italy by tracking their health over three years.

  Recruiting Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Milan · NCT06339255

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.